Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer

Lei-Jie Dai, Ding Ma (), Yu-Zheng Xu, Ming Li, Yu-Wei Li, Yi Xiao, Xi Jin, Song-Yang Wu, Ya-Xin Zhao, Han Wang, Wen-Tao Yang (), Yi-Zhou Jiang () and Zhi-Ming Shao ()
Additional contact information
Lei-Jie Dai: Fudan University Shanghai Cancer Center
Ding Ma: Fudan University Shanghai Cancer Center
Yu-Zheng Xu: Fudan University Shanghai Cancer Center
Ming Li: Fudan University Shanghai Cancer Center
Yu-Wei Li: Fudan University Shanghai Cancer Center
Yi Xiao: Fudan University Shanghai Cancer Center
Xi Jin: Fudan University Shanghai Cancer Center
Song-Yang Wu: Fudan University Shanghai Cancer Center
Ya-Xin Zhao: Fudan University Shanghai Cancer Center
Han Wang: Fudan University Shanghai Cancer Center
Wen-Tao Yang: Fudan University Shanghai Cancer Center
Yi-Zhou Jiang: Fudan University Shanghai Cancer Center
Zhi-Ming Shao: Fudan University Shanghai Cancer Center

Nature Communications, 2023, vol. 14, issue 1, 1-13

Abstract: Abstract The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of antibody‒drug conjugates. To address this issue, we established a cohort of 434 Chinese patients with HER2-low breast cancer (433 female and one male) and integrated genomic, transcriptomic, proteomic, and metabolomic profiling data. In this cohort, HER2-low tumors are more distinguished from HER2-0 tumors in the hormone receptor–negative subgroup. Within HER2-low tumors, significant interpatient heterogeneity also exists in the hormone receptor–negative subgroup: basal-like tumors resemble HER2-0 disease, and non-basal-like HER2-low tumors mimic HER2-positive disease. These non-basal-like HER2-low tumors are enriched in the HER2-enriched subtype and the luminal androgen receptor subtype and feature PIK3CA mutation, FGFR4/PTK6/ERBB4 overexpression and lipid metabolism activation. Among hormone receptor–positive tumors, HER2-low tumors show less loss/deletion in 17q peaks than HER2-0 tumors. In this work, we reveal the heterogeneity of HER2-low breast cancers and emphasize the need for more precise stratification regarding hormone receptor status and molecular subtype.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-40715-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40715-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-40715-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().